Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Meiji Seika Pharma said on August 22 that its local subsidiary has won regulatory approval in Thailand for the ROCK2 inhibitor Rezurock (belumosudil) to treat chronic graft-versus-host disease (cGVHD). The approval covers adult and pediatric patients aged 12 and older…
To read the full story
Related Article
- Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





